Knowthestock.com
CHRS - Coherus Biosciences Inc

Sell

Weak GrowthStock Price Very High
WeakStrong
WeakStrong

32%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 57.72%
Operating Income is Negative but improving
Net Income Growth is 159.67%
Earnings Per Share (EPS) is Negative but improving
Net Margin is 698.98%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 1.24
Debt Ratio is 0.83
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations is Negative
Capital Expenditure is Low
Net Increase in Cash is Negative
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Coherus Biosciences Inc (CHRS) - https://www.coherus.com/
coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp
Exchange - NASDAQ
Industry -
Sector -
CEO - Dennis Lanfear
Employees - 377
    Close

    Login/Register

    Home


Cookie Policy
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.